Drug Trial Radar · NCT06518291
COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN
Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
392
Planned (sponsor's estimate)
Start
Jan 2025
Primary completion
Jun 2025
Study completion Jun 2025
Sponsor
- Lead sponsor
- Shalamar Institute of Health SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 83 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Fosfomycin and nitrofurantoin are increasingly being prescribed in outpatients for the oral treatment of urinary tract infection (UTI). The newest guidelines for empirical treatment of women with uncomplicated urinary tract infections (UTIs) advise clinicians to choose among three venerable antibiotics: trimethoprim-sulfamethoxazole, nitrofurantoin, and fosfomycin. Although both nitrofurantoin and fosfomycin have shown efficacy against most urinary pathogens, no recent head-to-head comparisons have been reported. So, this study will be conducted to compare effectiveness of both drugs.
Conditions
- Urinary Tract Infections
Interventions
Nitrofurantoin 100 MGDrug
Comparing two drugs in UTI treatment
FosfomycinDrug
treatment of UTI
Primary outcomes
What the sponsor says the trial is designed to measure.
- clinical response following completion of therapy by historyTime frame: 7 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.